Inositol Nutritional Supplementation for the Prevention of Gestational Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Wei, J., Yan, J., & Yang, H. (2022). Inositol Nutritional Supplementation for the Prevention of Gestational Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients. https://doi.org/10.3390/nu14142831
Wei J, Yan J, Yang H. Inositol Nutritional Supplementation for the Prevention of Gestational Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients. 2022. doi:10.3390/nu14142831
Wei, Jingshu, et al. "Inositol Nutritional Supplementation for the Prevention of Gestational Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials." Nutrients, 2022.
For EndNote, Zotero or Mendeley:
Open access
No open license is recorded for this paper. Reuse terms are set by the publisher.
Open Access
Free full text on PubMed Central (PMC9318937)
RRM Academy Synopsis
Myo-inositol may lower gestational diabetes risk in pregnancy
In a meta-analysis of randomized trials in early-pregnancy women at higher risk, those who took myo-inositol alone developed gestational diabetes less often than controls (relative risk 0.30). That result comes from six trials and 995 women, within seven trials and 1321 women in all. A mixed inositol product showed no difference.
Key Findings
Six trials (n = 995) of myo-inositol alone: gestational diabetes incidence RR = 0.30, 95% CI (0.18, 0.49), p < 0.00001, with substantial heterogeneity (I2 = 52%).
Need for insulin treatment was lower with myo-inositol alone: RR = 0.27, 95% CI (0.11, 0.66), p = 0.004; four trials, n = 562.
Myo-inositol alone and preterm delivery, RR = 0.39, 95% CI (0.18, 0.82), four trials, n = 686; neonatal hypoglycemia, RR = 0.15, 95% CI (0.03, 0.66), five trials, n = 759.
The combined myo-inositol and D-chiro-inositol product showed no difference from control for gestational diabetes (p = 0.74; two trials, n = 326).
Across the seven studies and 1321 patients, no side effect was reported.
Interpretation
The review pools randomized trials of women in early pregnancy who had a higher chance of gestational diabetes. Women with type 1 or type 2 diabetes before pregnancy were left out. Six of the seven trials took place in Italy and one in Ireland. The authors conclude that myo-inositol alone may reduce gestational diabetes and the need for insulin. The combined product seemed inadequate for prevention. They rated the evidence quality as low or very low for every outcome. They call for studies in other countries and ethnic groups.
RRM Context
Past reports say inositol may lower insulin levels in women with PCOS. PCOS now has a new name, PMOS (Polyendocrine Metabolic Ovarian Syndrome). Insulin resistance is a shared thread in PCOS and gestational diabetes. Restorative reproductive medicine looks for such root causes.
Our editorial summary of this paper, not the article's abstract.
Abstract
This study was aimed at assessing the efficacy and safety of inositol nutritional supplementation during pregnancy for the prevention of GDM. PubMed, Embase, MEDLINE, and Cochrane library were systematically searched for randomized controlled trails (RCTs) in this field until May 2022. Primary outcomes were the incidence for GDM and plasma glucose levels by oral glucose tolerance test (OGTT). Pooled results were expressed as relative risk (RR) or mean difference (MD) with a 95% confidence interval (95% CI). Seven RCTs with 1321 participants were included in this study. Compared with the control group, 4 g myo-inositol (MI) supplementation per day significantly decreased the incidence of GDM (RR = 0.30, 95% CI (0.18, 0.49), p < 0.00001). It significantly decreased the plasma glucose levels of OGTT regarding fasting-glucose OGTT (MD = −4.20, 95% CI (−5.87, −2.54), p < 0.00001), 1-h OGTT (MD = −8.75, 95% CI (−12.42, −5.08), p < 0.00001), and 2-h OGTT (MD = −8.59, 95% CI (−11.81, −5.83), p < 0.00001). It also decreased the need of insulin treatment, and reduced the incidence of preterm delivery and neonatal hypoglycemia. However, no difference was observed between 1.1 g MI per day plus 27.6 mg D-chiro-inositol (DCI) per day and the control group regarding all evaluated results. In conclusion, 4 g MI nutritional supplementation per day during early pregnancy may reduce GDM incidence and severity, therefore may be a practical and safe approach for the prevention of GDM.